Relevant bibliographies by topics / Antiangiogenic treatment

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Antiangiogenic treatment'

Author: Grafiati
Published: 4 June 2021
Last updated: 27 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antiangiogenic treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antiangiogenic treatment"

1

Alfred, J. "Antiangiogenic cancer treatment." Trends in Genetics 14, no. 3 (1998): 91. http://dx.doi.org/10.1016/s0168-9525(98)01435-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhou, Jianhua, Wei Zheng, Longhui Cao, Min Liu, Feng Han, and Anhua Li. "Antiangiogenic Tumor Treatment." Academic Radiology 17, no. 5 (2010): 646–51. http://dx.doi.org/10.1016/j.acra.2010.01.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pimolbutr, Kununya, Stephen Porter, and Stefano Fedele. "Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature." BioMed Research International 2018 (2018): 1–14. http://dx.doi.org/10.1155/2018/8071579.

Full text
Abstract:
Objectives. To review the available literature on medication-related osteonecrosis of the jaw (MRONJ) associated with antiangiogenics in antiresorptive-naïve individuals. Methods. A literature search was performed using MEDLINE via PubMed, EMBASE, and Web of Science in December 2017. Results. We identified reports describing a total of 35 antiresorptive drugs-naïve patients who developed antiangiogenic-related MRONJ. The mean age of these patients was 59.06 years and the F : M ratio was 4 : 5. The most common underlying disease was metastatic renal cell cancer. Pain to the mandible was the mos
APA, Harvard, Vancouver, ISO, and other styles
4

Rahman, Md Ataur, and Meser M. Ali. "Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma." Cancers 16, no. 17 (2024): 2975. http://dx.doi.org/10.3390/cancers16172975.

Full text
Abstract:
Malignant gliomas present great difficulties in treatment, with little change over the past 30 years in the median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing the formation of new vasculature (antiangiogenic treatments) or destroying formed tumor vasculature (vascular disrupting agents) show promise. This study summarizes the existing knowledge regarding the processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses the activation of r
APA, Harvard, Vancouver, ISO, and other styles
5

Shinozaki, Eiji, Akitaka Makiyama, Yoshinori Kagawa, et al. "Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database." PLOS ONE 16, no. 2 (2021): e0246160. http://dx.doi.org/10.1371/journal.pone.0246160.

Full text
Abstract:
The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for
APA, Harvard, Vancouver, ISO, and other styles
6

Aguiar, Pedro, Tiago Costa de Pádua, Carmelia Maria Noia Barreto, and Auro del Giglio. "Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges." Clinical Medicine Insights: Urology 11 (January 1, 2018): 117956111876575. http://dx.doi.org/10.1177/1179561118765758.

Full text
Abstract:
Recently, the development of antiangiogenic drugs has changed the therapy for metastatic renal cell carcinoma (RCC). As a result, the survival of individuals with advanced RCC has more than doubled. The median overall survival improved from 12 months during the cytokines era to near 30 months with antiangiogenic drugs. In this decade, the advent of immune checkpoint inhibitors showed enthusiastic results and is the new standard of care for patients with metastatic RCC previously treated with antiangiogenic drugs. The combination of immune checkpoint inhibitors plus antiangiogenic drugs may hav
APA, Harvard, Vancouver, ISO, and other styles
7

López-Letayf, Sonia, Oscar Vivanco-Rojas, Valentina Londoño-Angarita, Fátima Sofía Magaña-Guerrero, Beatriz Buentello-Volante, and Yonathan Grafias. "Intravitreal Antiangiogenic Treatment for Diabetic Retinopathy: A Mexican Real-Life Scenario Experience." Life 14, no. 8 (2024): 976. http://dx.doi.org/10.3390/life14080976.

Full text
Abstract:
The objective of this study was to analyze the effectiveness of two intravitreal antiangiogenic drugs, ranibizumab and aflibercept, in a Mexican population over a period of 5 years, evaluating the improvement in visual acuity (VA) and central retinal thickness (CRT) in a real-world scenario. This is a retrospective study with subjects diagnosed with diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR), and diabetic macular edema (DME) receiving intravitreal injections of ranibizumab and/or aflibercept. In this study, we analyzed 588 eyes of 294 patients who received intravitreal
APA, Harvard, Vancouver, ISO, and other styles
8

Bartsch, Rupert, Anna S. Berghoff, Matthias Preusser, Guenther G. Steger, and Christoph C. Zielinski. "Antiangiogenic treatment approaches in breast cancer." Breast Cancer Management 2, no. 5 (2013): 397–406. http://dx.doi.org/10.2217/bmt.13.37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Riklin, Christian, Katharina Seystahl, Silvia Hofer, Caroline Happold, Ralph Winterhalder, and Michael Weller. "Antiangiogenic Treatment for Multiple CNS Hemangioblastomas." Onkologie 35, no. 7-8 (2012): 443–45. http://dx.doi.org/10.1159/000341075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Galsky, Matthew D. "Antiangiogenic treatment in metastatic urothelial cancer." Lancet Oncology 13, no. 8 (2012): 748–49. http://dx.doi.org/10.1016/s1470-2045(12)70319-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antiangiogenic treatment"

1

Benjamin, R. "Antiangiogenic strategies for the treatment of haematological malignancies." Thesis, University College London (University of London), 2012. http://discovery.ucl.ac.uk/1347244/.

Full text
Abstract:
Angiogenesis plays a key role in the pathogenesis of haematological malignancies such as acute myeloid leukaemia (AML), multiple myeloma (MM) and lymphoma (NHL). The evidence supporting this theory includes the finding of increased bone marrow microvessel density and increased levels of plasma and urinary pro-angiogenic cytokines in patients with these malignancies as well as encouraging results from preclinical and clinical studies using antiangiogenic therapies. A significant limiting factor in most of these studies has been the short half-life of most antiangiogenic compounds which has nece
APA, Harvard, Vancouver, ISO, and other styles
2

CUPPINI, LUCIA. "Antiangiogenic therapies for malignant gliomas: new markers for targeted treatment." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2012. http://hdl.handle.net/10281/28473.

Full text
Abstract:
Bevacizumab has shown activity in different tumor types, including high grade gliomas (HGG). However, the use of bevacizumab and other antiangiogenic drugs in the clinical setting limited by the lack of markers to predict responses. We report that the combined treatment with bevacizumab and irinotecan is effective in recurrent HGG patients, particularly in those with local disease, with mild toxicity. Median OS and PFS were 33 and 18 weeks, respectively. PFS at 6 and 12 months were 32% and 12%. OS at 6 months was 60%. Patients with distant intracerebral disease or leptomeningeal dissemination
APA, Harvard, Vancouver, ISO, and other styles
3

Knezevic, Zoran [Verfasser]. "Apelinergic system and its role in the development of resistance to antiangiogenic therapy in cancer treatment / Zoran Knezevic." Hamburg : Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky, 2020. http://d-nb.info/1222163365/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pourbaghi, Masouleh Milad. "Development of lipid nanocapsules for antiangiogenic treatment of glioblastoma and evaluation of their potential for nose-to-brain drug delivery." Thesis, Angers, 2018. http://www.theses.fr/2018ANGE0037.

Full text
Abstract:
Le glioblastome (GB), tumeur primitive du cerveau, la plus agressive, et la plus fréquente chez l’adulte, présente une prolifération vasculaire importante. Des agents thérapeutiques innovants ciblant à la fois l'angiogenèse et les cellules tumorales sont recherchés, ainsi que des systèmes pour augmenter leur délivrance dans la tumeur cérébrale. Un de ces agents est le sorafénib (SFN), un inhibiteur de tyrosine kinase. Sa mauvaise solubilité aqueuse et ses effets secondaires indésirables limitent son utilisation. Le premier objectif de cette thèse était d'encapsuler cet agent dans des nanocapsu
APA, Harvard, Vancouver, ISO, and other styles
5

Baron, Toaldo Marco <1981&gt. "Use of VEGFR-2 targeted microbubbles (BR55, Bracco imaging) for the early ultrasound evaluation of response to antiangiogenic treatment in a xenograft model of hepatocarcinoma." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/3478/1/BaronToaldo_Marco_tesi.pdf.

Full text
Abstract:
Aim: To evaluate the early response to treatment to an antiangiogenetic drug (sorafenib) in a heterotopic murine model of hepatocellular carcinoma (HCC) using ultrasonographic molecular imaging. Material and Methods: the xenographt model was established injecting a suspension of HuH7 cells subcutaneously in 19 nude mice. When tumors reached a mean diameter of 5-10 mm, they were divided in two groups (treatment and vehicle). The treatment group received sorafenib (62 mg/kg) by daily oral gavage for 14 days. Molecular imaging was performed using contrast enhanced ultrasound (CEUS), by injecting
APA, Harvard, Vancouver, ISO, and other styles
6

Baron, Toaldo Marco <1981&gt. "Use of VEGFR-2 targeted microbubbles (BR55, Bracco imaging) for the early ultrasound evaluation of response to antiangiogenic treatment in a xenograft model of hepatocarcinoma." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2011. http://amsdottorato.unibo.it/3478/.

Full text
Abstract:
Aim: To evaluate the early response to treatment to an antiangiogenetic drug (sorafenib) in a heterotopic murine model of hepatocellular carcinoma (HCC) using ultrasonographic molecular imaging. Material and Methods: the xenographt model was established injecting a suspension of HuH7 cells subcutaneously in 19 nude mice. When tumors reached a mean diameter of 5-10 mm, they were divided in two groups (treatment and vehicle). The treatment group received sorafenib (62 mg/kg) by daily oral gavage for 14 days. Molecular imaging was performed using contrast enhanced ultrasound (CEUS), by injecting
APA, Harvard, Vancouver, ISO, and other styles
7

Daudigeos, Dubus Estelle. "EVALUATION DE L’INHIBITION DE L’ANGIOGENESE DANS LE NEUROBLASTOME ET CARACTERISATION DE MECANISMES DE RESISTANCE." Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T096.

Full text
Abstract:
Adulte ou pédiatrique, les tumeurs solides ont besoin d’oxygène et de nutriments pour se développer et métastaser. Leur apport est assuré par la néo-vascularisation tumorale issue d’un processus multifactoriel appelé l’angiogénèse. Son équilibre est maintenu par une balance entre facteurs pro- et anti-angiogéniques. Elle fait partie des principales cibles pour traiter les cancers et l’inhibition de la voie VEGF en est un facteur clé. Cependant, la réponse aux agents anti-angiogéniques a montré, malgré des résultats encourageants, un effet transitoire associé à l’apparition d’une résistance ada
APA, Harvard, Vancouver, ISO, and other styles
8

"Antiangiogenic agents from tripterygium wilfordii for cancer treatment." Thesis, 2009. http://library.cuhk.edu.hk/record=b6074749.

Full text
Abstract:
Five traditional Chinese medicines were screened for their antiangiogenic activities through zebrafish angiogenic assay. Two of them, Tripterygium wilfordii and Rheum palmatum showed potential in the primary screening. T. wilfordii was selected in further study.<br>In the further investigation of antiangiogenic activity of triptolide on mammal systems, triptolide showed potent activity in human umbilical vein endothelial cells (HUVECs) assays including proliferation, migration and tube formation assay. It inhibited HUVEC proliferation with IC50 as low as 34 nM. It also showed more potency in H
APA, Harvard, Vancouver, ISO, and other styles
9

Basavarajappa, Halesha Dhurvigere. "The molecular mechanism of action of the antiangiogenic natural product, cremastranone." Diss., 2016. http://hdl.handle.net/1805/10690.

Full text
Abstract:
Indiana University-Purdue University Indianapolis (IUPUI)<br>Prevention of pathological angiogenesis is a key strategy for treatment of common blinding ocular diseases such as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related macular degeneration. The current treatment strategies are associated with partial vision loss and are ineffective in a significant patient population. Hence novel drugs as well as new ways to target ocular angiogenesis are needed for treating these diseases. I pursued a natural antiangiogenic compound, cremastranone, to develop nov
APA, Harvard, Vancouver, ISO, and other styles
10

Juan, Ting-Yi, and 阮婷儀. "Overcoming the Resistance of Antiangiogenetic Therapy Resulted from Tumor Microenvironment Alteration by the Synergy with Glucuronide Prodrug: Co-treatment in a Cancer Xenograft Mouse Model." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/42378697265445066553.

Full text
Abstract:
博士<br>國防醫學院<br>生命科學研究所<br>98<br>Renal cell carcinoma (RCC) accounts for 3% of all adult malignancies and clear cell RCC (ccRCC) is major type in renal cancer. The recent estimates of the cancer incidence worldwide about 208,000 new cases of kidney cancer have been diagnosed (1.9% of the world total), and 102,000 persons died because of kidney cancer in 2002. In Taiwan, there are 522 persons died because of kidney cancer in 2007, which is the 14th most common cause of cancer death in men and the 13th in women. Incidence and mortality rates are approximately 1.5 fold as high for men as for women
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antiangiogenic treatment"

1

1971-, Davis Darren W., Herbst Roy, and Abbruzzese James L, eds. Antiangiogenic cancer therapy. CRC Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Antiangiogenic cancer therapy. CRC Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Davis, Darren W., James L. Abbruzzese, and Roy S. Herbst. Antiangiogenic Cancer Therapy. Taylor & Francis Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Davis, Darren W., James L. Abbruzzese, and Roy S. Herbst. Antiangiogenic Cancer Therapy. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

(Editor), Darren W. Davis, Roy S. Herbst (Editor), and James L. Abbruzzese (Editor), eds. Antiangiogenic Cancer Therapy. CRC, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Davis, Darren W., James L. Abbruzzese, and Roy S. Herbst. Antiangiogenic Cancer Therapy. Taylor & Francis Group, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Davis, Darren W., James L. Abbruzzese, and Roy S. Herbst. Antiangiogenic Cancer Therapy. Taylor & Francis Group, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text
Abstract:
Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antiangiogenic treatment"

1

Cursiefen, Claus, and Felix Bock. "Antiangiogenic Treatment Options in the Cornea." In Corneal Disease. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-28747-3_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schättler, Heinz, and Urszula Ledzewicz. "Robust Suboptimal Treatment Protocols for Antiangiogenic Therapy." In Interdisciplinary Applied Mathematics. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2972-6_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bazzoli, Elena, and Antonio M. P. Omuro. "Antiangiogenic Strategies for the Treatment of Gliomas." In Glioblastoma. Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-0410-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mir, Manzoor Ahmad, Asma Jan, Aisha Shabir, and Burhan Ul Haq. "The Antiangiogenic Basis of Metronomic Chemotherapy." In Novel Approaches in Metronomic Chemotherapy for Breast Cancer Treatment. CRC Press, 2024. http://dx.doi.org/10.1201/9781032632674-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Citrin, Deborah, and Kevin Camphausen. "Advancement of Antiangiogenic and Vascular Disrupting Agents Combined with Radiation." In Cancer Treatment and Research. Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-36744-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Obad, Nina, and Rolf Bjerkvig. "The Implication of Antiangiogenic Treatment of Malignancies on Human Metabolism." In Tumor Angiogenesis. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-31215-6_35-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cemazar, M., T. Dolinsek, N. Tesic, M. Stimac, and G. Sersa. "Electrotransfer of Antiangiogenic shRNA against Endoglin for Effective Cancer Treatment." In 1st World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-287-817-5_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shaked, Yuval, Paul Nathan, Laura G. M. Daenen, and Robert S. Kerbel. "Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action." In Vascular Disruptive Agents for the Treatment of Cancer. Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6609-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Buikhuisen, Wieneke, and Paul Baas. "Antiangiogenic Therapies for Mesothelioma: What Is the Role in Mesothelioma Treatment?" In Malignant Pleural Mesothelioma. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-9158-7_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ayodele, Olubukola, and Lillian L. Siu. "New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_23.

Full text
Abstract:
AbstractChemotherapy has been the backbone for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RMNPC), which remains an incurable disease. Currently the most active area of therapeutic investigations in RMNPC is in immunotherapy, especially after the results of five anti-programmed death-1 (anti-PD-1) antibodies, i.e. pembrolizumab, nivolumab, camrelizumab, toripalimab and tislelizumab, have demonstrated monotherapy objective response rates of 21%–43%. Combinations using anti-PD1/L1 antibodies as backbone to evaluate their additivity or synergy with cytotoxic chemotherapy, m
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antiangiogenic treatment"

1

Mitsuhashi, Atsushi, Tania Afroj, Atsuro Saijo, et al. "The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Adotevi, Olivier, Fabien Calcagno, Tristan Maurina, et al. "Abstract 2588: Antiangiogenic and immunomodulatory effects of metronomic cyclophosphamide (CPM) treatment in prostate cancer patients with PSA failure." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2588.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fernández-Ginés, FD, TB Rodríguez-Cuadros, S. Cañizares Paz, and E. Molina-Cuadrado. "CP-023 Use of intravitreal antiangiogenic drug in a large study in the treatment of retinopathy of prematurity." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Wei, Giulia Fulci, Samuel D. Rabkin, Xiang Zhang, and Robert L. Martuza. "Abstract 2568: Combination treatment of bevacizumab and oncolytic HSV armed with angiostatin show enhanced antitumoral and antiangiogenic effects." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-2568.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Williams, Shante’ P., Michal O. Nowicki, E. Antonio Chiocca, and Sean E. Lawler. "Abstract LB-293: Indirubins decrease glioma growth and invasionin vivo:A novel treatment paradigm combining antimigratory and antiangiogenic effects." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-293.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Alani, Adam G., and Gyan Mishra. "Abstract 5664: The antiangiogenic effect of two drugs loaded nanocarriers and its potential application for cancer metronomic treatment." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5664.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rivera, Maria, Michael Becker, Peter M. Schlag, et al. "Abstract 4524: Characterization of 28 patient derived colorectal cancer xenografts and analysis for response markers to an antiangiogenic treatment." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4524.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mondejar, Tamara, Elena Hernadez-Agudo, Marisa Soto-Montenegro, et al. "Abstract 1493: 18F-misonidazole PET (FMISO-PET) monitors vascular normalization (VN) and predicts benefit from antiangiogenic treatment plus chemotherapy in pancreas cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1493.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Provent, Peggy, Marc Hillairet de Boisferon, Zina Koob, Francis Bichat, and Xavier Tizon. "Abstract 2447: Measurement of tumor vascular integrity changes in an orthotopic glioma model in rats induced by antiangiogenic treatment using DCE-MRI." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2447.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hashimoto, Kae, Shan Man, Ping Xu, et al. "Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-a9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antiangiogenic treatment"

1

Yu, Winifred, Elise Digga, Courtney Luterbach, et al. Association Between Outcomes and Dental Services in People Receiving Treatments That Cause Medication-Related Osteonecrosis of the Jaw: A Rapid Response Review. AHRQ, 2025. https://doi.org/10.23970/ahrqepc_rapid_dental_jaw.

Full text
Abstract:
This review is undertaken to answer the following questions: Key Question 1: What is the effectiveness of dental services in improving health outcomes in people receiving treatments that cause medication-related osteonecrosis of the jaw (MRONJ) before, during, or after treatment with bisphosphonates, antiangiogenics, and other drugs for conditions other than cancer? Key Question 2: What are the clinical practice guidelines or standards for dental care for people receiving treatments that cause MRONJ? Key Messages: The body of evidence informing KQ1 consists of two randomized clinical trials (R
APA, Harvard, Vancouver, ISO, and other styles
2

Basu, Sujit. Role of Dopamine as Antiangiogenic Agent in the Treatment of Prostate Cancer. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada482221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antiangiogenic treatment' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography